Xtant Medical (XTNT) reports Q1 2026 earnings with revenue of $20.9M, raising full-year guidance to $101M-$105M. Read more on strategic initiatives.

Key Takeaways

• First quarter 2026 revenue was $20.9 million, down from $32.9 million in Q1 2025.
• The company raised its full-year revenue guidance to $101 million to $105 million due to strong product launches and strategic acquisitions.
• Total indebtedness decreased by $13.3 million in Q1 2026, significantly improving the company’s balance sheet.
• The company reported a net loss of $3.1 million or $0.02 per share compared to a net income of $58,000 in Q1 2025.
• Gross margin for Q1 2026 was 57.3%, down from 61.5% in the prior year, primarily due to changes in the product mix and the cessation of prior revenue streams.

Financial Performance

Xtant Medical Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $20.9 million. This marks a significant decline compared to the same quarter last year, where revenue stood at $32.9 million. However, it's essential to note that the previous year's figures included revenue from non-core products that were divested. On a pro forma basis, the decline is more nuanced, with revenue down from $23.9 million when excluding these non-recurring earnings.

Gross margin stood at 57.3%, a decrease from 61.5% in Q1 2025, primarily due to the end of the Q Code license revenue from amniotic membrane agreements, coupled with a less favorable product mix. However, operating expenses decreased by $4.3 million to $14.9 million for the quarter, reflecting cost-cutting measures following the sale of non-core assets.

The company reported a net loss of $3.1 million or $0.02 per share, a notable shift from a net income of $58,000 in Q1 2025. Adjusted EBITDA also reflected a loss of $1.6 million, diverging from the $3 million profit reported in the same period last year. Despite the loss, Xtant Medical’s strategic focus on biologics positions it for future growth, as highlighted by the guidance for 2026.

Strategic Initiatives

Xtant Medical has undertaken several strategic initiatives to bolster its position in the market. The most notable is the exclusive distribution agreement with Dillon Technologies, which grants the company rights to distribute the hemoblast Bellows product. This product is expected to significantly enhance Xtant Medical's offerings and is projected to tap into a $2 billion global market for hemostatic agents. The hemostatic agent is distinguished by its unique formulation containing collagen and human-derived thrombin, making it versatile across various surgical applications.

Additionally, the company has launched the Trivium Shaped, an advanced bone graft product designed to optimize surgical workflows. This new offering expands upon the success of the existing Trivium line and is anticipated to meet the needs of surgeons more effectively, thereby enhancing Xtant Medical’s competitive edge in the orthopedic market.

In tandem with these product launches, Xtant Medical has also expanded its sales force by hiring 21 sales professionals from Dillon Technologies. This move is part of a broader strategy to double the company's regional sales representatives in 2026. The enhancement of the sales team is expected to drive institutional adoption and increase the scalability of its product offerings across hospital systems and large practice groups.

Future Outlook

Management has expressed optimism about the company's future, raising its full-year revenue guidance to a range of $101 million to $105 million. This adjustment reflects the anticipated contributions from the new product launches and the strengthening of its commercial organization. The company expects that the combination of these initiatives will drive accelerating growth in the biologics segment for the remainder of 2026 and beyond.

Xtant Medical also plans to focus on its core high-margin biologics business, which has shown a more favorable growth trajectory compared to its previously divested non-core operations. By strategically investing in its commercial enterprise, the company aims to leverage its enhanced product portfolio to gain further market share.

Management also acknowledged the importance of monitoring gross margin trends, projecting that the gross margin may bounce back to the low 60s for the latter half of 2026, contingent upon product mix improvements and operational efficiencies.

In summary, Xtant Medical’s proactive initiatives, including strategic partnerships, new product introductions, and a robust sales force expansion, position the company to capitalize on growth opportunities in the evolving healthcare landscape. Despite current challenges reflected in the financial results, the company’s focused strategy and improved balance sheet instill confidence in its path forward.

In conclusion, while the financial performance in the first quarter of 2026 showcased some setbacks, the strategic initiatives undertaken by Xtant Medical hold promise for future growth. The company's commitment to innovation and operational efficiency will likely play a critical role in navigating the complexities of the healthcare market.

This analysis is based on public earnings call materials and is not investment advice.